Erythropoietin single nucleotide polymorphisms are associated with anemia and dyslipidemia in a cardiovascular disease population
Rattachement africain : ca. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Human erythropoietin (EPO) is an essential erythropoietic cytokine and recombinant biological therapeutic in anemia in chronic kidney disease. Single nucleotide polymorphisms (SNPs) in EPO have been linked to anemia and diabetic microvascular complications but no other cardiovascular comorbidities like dyslipidemia or hypertension. Here identified a clinical cohort of cardiovascular patients with anemia, dyslipidemia, hypertension, type-2 diabetes, or heart failure with preserved ejection fraction. Sanger sequencing was used for genotyping three EPO SNPs (rs1617640, rs507392 and rs551238), which were compared to clinical outcomes with SNPstat and clinical parameters profiles by student t-test. Nonstandard clinical chemistry measures of plasma EPO, hepcidin, transferrin, and ferritin were determined by ELISA. In the additive model, the C allele of rs1617640 was associated with lower EPO and anemia. In the recessive model, the SNP rs507392 genotype of GG was associated with dyslipidemia, which was associated with lower EPO in plasma and elevated total cholesterol and low-density lipoproteins. Interestingly, the G allele of rs507392 was found to be associated with hypertension, but only in females. Here we show that the SNPs in EPO are a potential risk factor for anemia, dyslipidemia, and hypertension in cardiovascular disease patients.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Erythropoietin single nucleotide polymorphisms are associated with anemia and dyslipidemia in a cardiovascular disease population
- Date Crossref
- 26/09/2024
- Éditeur
- openRxiv
- Type
- posted-content
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Dalhousie University Department of Pharmacology pays non établi dans la noticeUniversité ou école supérieure
-
Saint John Regional Hospital Departments of Cardiology & Cardiac Surgery pays non établi dans la noticeÉtablissement de santé
-
University of Guelph Department of Human Health and Nutritional Sciences pays non établi dans la noticeUniversité ou école supérieure
-
Dalhousie Medicine New Brunswick pays non établi dans la noticeInstitution
-
IMPART investigator team Canada () pays non établi dans la noticeInstitution
Department of Pharmacology — Dalhousie University, Departments of Cardiology & Cardiac Surgery — Saint John Regional Hospital et Department of Human Health and Nutritional Sciences — University of Guelph, avec 2 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.